ArticleCirculation. Heart failure2021
Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8
Article in Circulation. Heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.Frontiers in medicine · 2022Pooled it
- Review
- PD-1/PD-L1 Signaling in Non-ICI Myocarditis.JACC. Basic to translational science · 2026Article
- Immune-Checkpoint-Inhibitor-Related Cardiovascular Toxicities in Cancer: A Mechanistic Review of Molecular Pathways with AI-Assisted Literature Clustering.International journal of molecular sciences · 2026Review
- Expression of PD-1/PD-L1 pathway molecules in human cardiac allograft according to acute cellular rejection status: insights from a Korean Heart Transplant Cohort.Journal of pathology and translational medicine · 2026Article
- A call to redefine cardiovascular immunobiology around leukocyte plasticity.American journal of physiology. Heart and circulatory physiology · 2026Article
- Nicotinamide prevents anti-PD1 immune checkpoint inhibitor-associated early stages of cardiotoxicity.Science China. Life sciences · 2026Article
- Transcriptional signatures of endothelial cells shape immune responses in cardiopulmonary health and disease.JCI insight · 2025Review
- Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.Nature reviews. Cardiology · 2024Review
- Endothelial cells adopt a pro-reparative immune responsive signature during cardiac injury.Life science alliance · 2024Article
- Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients - A Review of Potential Complications and Management Strategies.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Effects of a Small-Molecule Perforin Inhibitor in a Mouse Model of CD8 T Cell-Mediated Neuroinflammation.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Antithymocyte Globulin Inhibits CD8Cells · 2023Article
- Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?Frontiers in immunology · 2023Review
- New insights into maladaptive vascular responses to donor specific HLA antibodies in organ transplantation.Frontiers in transplantation · 2023Review
- Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.Cell reports · 2022Article
- Costimulation blockade and Tregs in solid organ transplantation.Frontiers in immunology · 2022Review
- Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?Frontiers in immunology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
Abstract
backgroundThe role of checkpoint axes in transplantation has been partially addressed in animal models but not in humans. Occurrence of fulminant myocarditis with allorejection-like immunologic features in patients under anti-PD1 (programmed death cell protein 1) treatment suggests a key role of the PD1/PD-L1 (programmed death ligand 1) axis in cardiac immune homeostasis.
methodsWe cross-sectionally studied 23 heart transplant patients undergoing surveillance endomyocardial biopsy. Endomyocardial tissue and peripheral blood mononuclear cells were analyzed by flow cytometry. Multivariate logistic regression analyses including demographic, clinical, and hemodynamic parameters were performed. Murine models were used to evaluate the impact of PD-L1 endothelial graft expression in allorejection.
resultsWe found that myeloid cells dominate the composition of the graft leukocyte compartment in most patients, with variable T-cell frequencies. The CD (cluster of differentiation) 4:CD8 T-cell ratios were between 0 and 1.5. The proportion of PD-L1 expressing cells in graft endothelial cells, fibroblasts, and myeloid leukocytes ranged from negligible up to 60%. We found a significant inverse logarithmic correlation between the proportion of PD-L1
conclusionsLoss of graft endothelial PD-L1 expression may play a role in regulating CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.